Romiplostim (AMG-531)

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Conditions

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Trial Timeline

Feb 1, 2006 → Nov 1, 2006

About Romiplostim (AMG-531)

Romiplostim (AMG-531) is a phase 2 stage product being developed by Kyowa Kirin for Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT00305435. Target conditions include Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00305435Phase 2Completed

Competing Products

20 competing products in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

See all competitors